C3-targeted therapy in periodontal disease: moving closer to the clinic.

Hajishengallis, George; Hasturk, Hatice; Lambris, John D (2021). C3-targeted therapy in periodontal disease: moving closer to the clinic. Trends in immunology, 42(10), pp. 856-864. Elsevier Current Trends 10.1016/j.it.2021.08.001

Text 1-s2.0-S1471490621001538-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB)

Complement plays a key role in immunosurveillance and homeostasis. When dysregulated or overactivated, complement can become a pathological effector, as seen in several inflammatory disorders, including periodontal disease. Recently, clinical correlative studies and preclinical mechanistic investigations have collectively demonstrated that complement is hyperactivated during periodontitis and that targeting its central component (C3) provides therapeutic benefit in nonhuman primates (NHPs). The preclinical efficacy of a C3-targeted drug candidate combined with excellent safety and pharmacokinetic profiles supported its use in a recent Phase IIa clinical study in which C3 inhibition resolved gingival inflammation in patients with periodontal disease. We posit that C3-targeted intervention might represent a novel and transformative host-modulation therapy meriting further investigation in Phase III clinical trials for the treatment of periodontitis.

Interest & Impact

Downloads

1 since deposited on 08 Mar 2022
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item